Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

B 244

Next Previous
Drug Profile

B 244

Alternative Names: AOB 101; AOB 102; AOB 103; AOB 201; AOB 202; AOB 203; B244; Nitrosomonas eutropha D23

Latest Information Update: 08 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AOBiome
  • Developer AOBiome; Novella Clinical
  • Class Anti-inflammatories; Antiacnes; Antiallergics; Antibacterials; Antihypertensives; Antimigraines; Antipruritics; Bacteria; Skin disorder therapies
  • Mechanism of Action Bacteria replacements; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Acne vulgaris
  • Phase II Atopic dermatitis; Hypertension; Pruritus; Rosacea
  • Phase I/II Allergic rhinitis; Eczema
  • No development reported Migraine; Skin disorders; Staphylococcal infections

Most Recent Events

  • 02 Dec 2025 AOB Pharma plans to file the initial Market Authorization Application (MAA) to the EMA
  • 02 Dec 2025 AoBiome Therapeutics plans phase III trials in Atopic dermatitis (In children, In adolescents and In adults) in the European Union
  • 05 Jan 2024 AoBiome Therapeutics plans phase III trials in Atopic dermatitis in the second half of 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top